351 related articles for article (PubMed ID: 38632167)
1. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.
Liu Y; Li C; Liu H; Tan S
Arch Pharm Res; 2024 May; 47(5):442-464. PubMed ID: 38632167
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
Lu X; Xiao L; Wang L; Ruden DM
Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitors as promising agents for radiotherapy.
Kabakov AE; Kudryavtsev VA; Gabai VL
J Mol Med (Berl); 2010 Mar; 88(3):241-7. PubMed ID: 19946660
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
Li ZN; Luo Y
Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36367182
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
7. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.
Ren X; Li T; Zhang W; Yang X
Cells; 2022 Aug; 11(16):. PubMed ID: 36010632
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
10. Hsp90: a novel target for cancer therapy.
Solit DB; Rosen N
Curr Top Med Chem; 2006; 6(11):1205-14. PubMed ID: 16842157
[TBL] [Abstract][Full Text] [Related]
11. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy.
Xie X; Zhang N; Li X; Huang H; Peng C; Huang W; Foster LJ; He G; Han B
Bioorg Chem; 2023 Oct; 139():106721. PubMed ID: 37467620
[TBL] [Abstract][Full Text] [Related]
13. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
14. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Li Y; Zhang T; Schwartz SJ; Sun D
Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
[TBL] [Abstract][Full Text] [Related]
15. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
19. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
Li L; Chen NN; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
[TBL] [Abstract][Full Text] [Related]
20. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
